- Home
- JXG vs ASBP Comparison
JXG vs ASBP Comparison
Compare JXG & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- ASBP
- Stock Information
- Founded
- JXG N/A
- ASBP 2021
- Country
- JXG China
- ASBP United States
- Employees
- JXG N/A
- ASBP N/A
- Industry
- JXG
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- ASBP Health Care
- Exchange
- JXG Nasdaq
- ASBP Nasdaq
- Market Cap
- JXG 16.9M
- ASBP 18.9M
- IPO Year
- JXG N/A
- ASBP N/A
- Fundamental
- Price
- JXG $0.51
- ASBP $0.11
- Analyst Decision
- JXG
- ASBP
- Analyst Count
- JXG 0
- ASBP 0
- Target Price
- JXG N/A
- ASBP N/A
- AVG Volume (30 Days)
- JXG 216.1K
- ASBP 61.2M
- Earning Date
- JXG 12-05-2025
- ASBP 11-14-2025
- Dividend Yield
- JXG N/A
- ASBP N/A
- EPS Growth
- JXG N/A
- ASBP N/A
- EPS
- JXG 0.35
- ASBP N/A
- Revenue
- JXG $46,835,624.00
- ASBP $1,941.00
- Revenue This Year
- JXG N/A
- ASBP N/A
- Revenue Next Year
- JXG N/A
- ASBP N/A
- P/E Ratio
- JXG $1.52
- ASBP N/A
- Revenue Growth
- JXG 21.68
- ASBP N/A
- 52 Week Low
- JXG $0.48
- ASBP $0.09
- 52 Week High
- JXG $6.12
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- JXG 25.18
- ASBP 27.81
- Support Level
- JXG $0.55
- ASBP $0.09
- Resistance Level
- JXG $0.59
- ASBP $0.16
- Average True Range (ATR)
- JXG 0.06
- ASBP 0.05
- MACD
- JXG -0.01
- ASBP -0.02
- Stochastic Oscillator
- JXG 9.76
- ASBP 4.96
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Tourism products, Technology, and Cross board merchandise The majority of the group revenue is generated from Tourism products.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.